Table 2. Baseline characteristics of the two study groups.
| Transplant variables | Low Tregs/CD4+ T cells (n=47) | High Tregs/CD4+ T cells (n=47) | P-value |
|---|---|---|---|
| Treg/CD4+ T cells, median (range) | 0.022 (0.008–0.029) | 0.039 (0.030–0.086) | <0.0001 |
| Recipient | |||
| Age (years), median (range) | 49 (18–66) | 48 (19–74) | 0.73 |
| CMV serology, neg/pos | 24/23 | 24/23 | 1.00 |
| Disease, acute leuk/other | 23/24 | 24/23 | 0.84 |
| Disease status, early/other | 23/24 | 23/24 | 1.00 |
| Donor | |||
| Age (years), median (range) | 39 (19–59) | 42 (19–72) | 0.02 |
| CMV serology, neg/pos | 31/16 | 33/14 | 0.66 |
| Recipient/donor | |||
| Gender (R:D), M:F/other | 37/10 | 40/7 | 0.42 |
| ABO mismatch, minor/major | 38/9 | 38/9 | 1.00 |
| HLA mismatch (HvG), no/yes | 39/8 | 41/6 | 0.56 |
| HLA mismatch (GvH), no/yes | 38/9 | 41/6 | 0.40 |
| Transplant | |||
| Donor, sibling/unrelated | 12/35 | 26/21 | 0.003 |
| Conditioning, MAC/RIC | 9/38 | 5/42 | 0.25 |
| Alemtuzumab, no/yes | 12/35 | 24/23 | 0.01 |
| PBSC graft | |||
| TNC (× 108/kg), median (range) | 9.0 (4.0–24.9) | 10.7 (2.7–37.6) | 0.39 |
| CD34+ (× 106/kg), median (range) | 6.5 (1.1–9.4) | 6.1 (1.5–19.8) | 0.99 |
| CD3+ (× 106/kg), median (range) | 296 (92–793) | 253 (87–801) | 0.30 |
| CD3+CD4+ (× 106/kg), median (range) | 175 (50–694) | 166 (50–504) | 0.23 |
| CD3+CD8+ (× 106/kg), median (range) | 85 (36–187) | 78 (26–248) | 0.32 |
| CD19+ (× 106/kg), median (range) | 61 (13–245) | 63 (20–234) | 0.36 |
| CD3−CD56+ (× 106/kg), median (range) | 35 (9–101) | 35 (8–100) | 0.95 |
Abbreviations: acute leuk=acute leukaemia; HvG=host-versus-graft; M:F=male:female; MAC=myeloablative; R:D=recipient:donor; RIC=reduced intensity; TNC=total nucleated cells.
Low Tregs/CD4+ T cells (<0.0296); High Tregs/CD4+ T cells (>0.0296).
Significant variables (P<0.05) shown in bold.